生物制药公司Longeveron Inc近日披露了其研发管线的最新进展。公司宣布,针对罕见先天性心脏病——左心发育不全综合征(HLHS)的2B期临床试验,预计将在2026年第三季度正式启动。这一关键性临床试验的推进,标志着公司在细胞疗法治疗严重心脏病领域迈出了重要一步。
生物制药公司Longeveron Inc近日披露了其研发管线的最新进展。公司宣布,针对罕见先天性心脏病——左心发育不全综合征(HLHS)的2B期临床试验,预计将在2026年第三季度正式启动。这一关键性临床试验的推进,标志着公司在细胞疗法治疗严重心脏病领域迈出了重要一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.